Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 11/20 | 0.61 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12704627 | 0.90 | PTGS1 (0.49) | PTGS1NR1H3PTPN1 | |
| SCHEMBL6008324 | 0.89 | PTGS1 (0.48) | PTGS1NR1H3PTPN1 | |
| SCHEMBL12704628 | 0.89 | PTGS1 (0.62) | PTGS1NR1H3PTPN1 | |
| SCHEMBL12887596 | 0.86 | PTGS1 (0.46) | PTGS1NR1H3PTPN1 | |
| SCHEMBL267926 | 0.86 | NR1H3 (0.58) | PTGS1NR1H3PTPN1 | |
| SCHEMBL14286750 | 0.86 | NR1H3 (0.58) | PTGS1NR1H3PTPN1 | |
| SCHEMBL12450206 | 0.86 | NR1H3 (0.58) | PTGS1NR1H3PTPN1 | |
| SCHEMBL14112005 | 0.84 | PTGS1 (0.56) | PTGS1NR1H3PTPN1 | |
| SCHEMBL14112376 | 0.84 | NR1H3 (0.42) | PTGS1NR1H3PTPN1 | |
| SCHEMBL6008298 | 0.84 | NR1H3 (0.58) | PTGS1NR1H3PTPN1RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188475-A1 | Novel Interleukin-1 and Tumor Necrosis Factor-Alpha Modulators, Syntheses of Said Modulators and Their Enantiomers and Methods of Using Said Modulators | NEREUS PHAMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080103328-A1 | Novel Interleukin-1 and Tumor Necrosis Factor-Alpha Modulators, Syntheses of Said Modulators and Their Enantiomers and Methods of Using Said Modulators | NEREUS PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103328-A1 | Novel Interleukin-1 and Tumor Necrosis Factor-Alpha Modulators, Syntheses of Said Modulators and Their Enantiomers and Methods of Using Said Modulators | TNF, TNFRSF1A, IL1R1 | PTGS1 93/4885NR1H3 466/4885PTPN1 3239/4885 |
| US-20080188475-A1 | Novel Interleukin-1 and Tumor Necrosis Factor-Alpha Modulators, Syntheses of Said Modulators and Their Enantiomers and Methods of Using Said Modulators | IL1A, IL1B, TNF | PTGS1 11/4885NR1H3 1132/4885PTPN1 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.